SuperworthExagen profit margin XGN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2019.
- Net margin, 12 months
- −26.6%
- Operating margin, 12 months
- −18.6%
- Net margin on a year earlier
- +2.2 pts
- Peer median
- 7.3%
Over the twelve months to Jun 30, 2026, Exagen kept −26.6% of its revenue as net profit, with an operating margin of −18.6% and a gross margin of 58.6%.
Five years earlier its net margin was −43.5%.
The median for 10 healthcare stocks of a similar size is 7.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −30.0% | −21.1% | 58.3% |
| FY2024 | −27.2% | −24.5% | 59.5% |
| FY2023 | −45.1% | −43.5% | 56.1% |
| FY2022 | n/a | n/a | 46.9% |
| FY2021 | −55.6% | −49.8% | 57.4% |
| FY2020 | −39.8% | −36.2% | 60.6% |
| FY2019 | −29.8% | −23.0% | 53.4% |
| FY2018 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −26.6% | +2.2 pts | −18.6% | |
| Q1 FY26 | −29.5% | −2.2 pts | −20.6% | |
| Q4 FY25 | −30.0% | −2.8 pts | −21.1% | |
| Q3 FY25 | −29.9% | +0.4 pts | −19.6% | |
| Q2 FY25 | −28.8% | +1.7 pts | −23.9% | |
| Q1 FY25 | −27.3% | +7.4 pts | −24.7% | |
| Q4 FY24 | −27.2% | +17.9 pts | −24.5% | |
| Q3 FY24 | −30.4% | +32.5 pts | −27.6% | |
| Q2 FY24 | −30.6% | +35.9 pts | −27.9% | |
| Q1 FY24 | −34.7% | +61.8 pts | −32.5% | |
| Q4 FY23 | −45.1% | n/a | −43.5% | |
| Q3 FY23 | −62.9% | +25.4 pts | −62.3% |
Against its peers
Companies in Healthcare nearest Exagen's size, closest first, today.
| Company | Profit margin |
|---|---|
| XGNExagen | −26.6% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| ELMDElectromed | 15.3% |
| UTMDUtah Medical Products | 29.0% |
| INFUInfuSystem | 6.0% |
| KEQUKewaunee Scientific | 3.0% |
| ICCCImmucell | 2.6% |
| VMDViemed Healthcare | 4.8% |
| EMBCEmbecta | 8.6% |
| Peer median | 7.3% |
Where Exagen ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Exagen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.